IP Library › Granted Patent US 12,441,743
Granted Patent B2
US 12,441,743 · App. 18/196,357 · Granted Oct 14, 2025

Spiro aromatic ring compound and use thereof

Inventors: Qiangang Zheng (Shanghai, CN); Ming Xu (Shanghai, CN); Qinglong Zeng (Shanghai, CN); Jing Li (Shanghai, CN); Hao Zhuge (Shanghai, CN)
Assignee: Etern Biopharma (Shanghai) Co., Ltd.
C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,441,743
App. No.
18/196,357
Granted
Oct 14, 2025
Kind
B2
Abstract

Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.

Claims (41)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereoisomer, tautomer, solvate, isotope-substituted derivative, polymorph, prodrug or metabolite thereof, wherein:

X 1 and X 2 are independently selected from a bond, O, CR a R b or NR c ;

X 3 is selected from a bond, CR a R b , NR c , S or O;

X 4 is selected from N or CR c ; and R a , R b and R c are independently selected from H, halogen, substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxyl;

R 1 , R 2 , R 3 , R 4 and R 7 are independently selected from H, —OH, halogen, substituted or unsubstituted amino, substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxyl; and R 1 , R 2 , R 3 , R 4 and R 7 cannot be —OH or —NH 2 simultaneously;

ring A is selected from substituted or unsubstituted C 4-8 cyclic hydrocarbyl, substituted or unsubstituted 4 to 8-membered heterocyclyl, substituted or unsubstituted C 5-10 aryl, or substituted or unsubstituted 5 to 10-membered heteroaryl, wherein the heterocyclyl or heteroaryl comprises 1-3 heteroatoms selected from: N, O, S or P;

ring C is selected from substituted or unsubstituted C 4-8 cyclic hydrocarbyl, substituted or unsubstituted 5 to 6-membered monocyclic heterocyclyl, substituted or unsubstituted 8 to 10-membered bicyclic heterocyclyl, substituted or unsubstituted C 5-10 monocyclic or bicyclic aryl, substituted or unsubstituted 5 to 6-membered monocyclic heteroaryl, or substituted or unsubstituted 8 to 10-membered bicyclic heteroaryl, wherein the heterocyclyl or heteroaryl comprises 1-4 heteroatoms selected from: N, O, S or P;

R 5 and R 6 are independently selected from H, —OH, halogen, cyano, substituted or unsubstituted amino, substituted or unsubstituted C 1-6 alkyl, or substituted or unsubstituted C 1-6 alkoxyl;

n is any integer from 0 to 3; and

wherein the term “substituted” refers to one or more hydrogen atoms on the group are substituted by a substituent selected from: halogen, —OH, —NO 2 , —NH 2 , —NH(unsubstituted or halogenated C 1-6 alkyl), —N(unsubstituted or halogenated C 1-6 alkyl) 2 , —CN, unsubstituted or halogenated C 1-8 alkyl, unsubstituted or halogenated C 1-8 alkoxyl, unsubstituted or halogenated C 1-8 alkoxyl-C 1-8 alkyl, unsubstituted or halogenated C 3-8 cycloalkyl-C 1-8 alkyl, unsubstituted or halogenated C 1-6 alkyl carbonyl, unsubstituted or halogenated C 1-6 alkoxyl carbonyl, hydroxamic acid group, unsubstituted or halogenated C 1-6 alkyl thiol, —S(O) 2 N(unsubstituted or halogenated C 1-6 alkyl) 2 , —S(O) 2 unsubstituted or halogenated C 1-6 alkyl, —N(unsubstituted or halogenated C 1-6 alkyl)S(O) 2 N(unsubstituted or halogenated C 1-6 alkyl) 2 , —S(O)N(unsubstituted or halogenated C 1-6 alkyl) 2 , —S(O)(unsubstituted or halogenated C 1-6 alkyl), —N(unsubstituted or halogenated C 1-6 alkyl)S(O)N(unsubstituted or halogenated C 1-6 alkyl) 2 , —N(unsubstituted or halogenated C 1-6 alkyl)S(O)(unsubstituted or halogenated C 1-6 alkyl), unsubstituted or halogenated C 5-10 aryl, unsubstituted or halogenated 5 to 10-membered heteroaryl, unsubstituted or halogenated C 4-8 cyclic hydrocarbyl, or unsubstituted or halogenated 4 to 8-membered heterocyclyl, wherein the heterocyclyl and heteroaryl comprise 1-4 heteroatoms selected from: N, O or S.

2. The compound of Formula I of claim 1 , wherein one of X 1 and X 2 is CH 2 , and the other is a bond.

3. The compound of Formula I of claim 1 , wherein X 3 is S.

4. The compound of Formula I of claim 1 , wherein X 4 is selected from N or CH.

5. The compound of Formula I of claim 1 , wherein R 1 , R 2 , R 3 , R 4 and R 7 are independently selected from H, —OH, —F, —Cl, —Br, —NH 2 , —NHC 1-3 alkyl, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, propoxy or isopropoxy; C 1-3 alkyl substituted by halogen, —NH 2 , —OH, C 1-3 alkyl or C 1-3 alkoxyl; or C 1-3 alkoxyl substituted by halogen, —NH 2 , —OH, C 1-3 alkyl or C 1-3 alkoxyl.

6. The compound of Formula I of claim 1 , wherein R 5 and R 6 are independently selected from H, —F, —Cl, —Br, —CN, —NH 2 , —NHC 1-3 alkyl, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, propoxy or isopropoxy; C 1-3 alkyl substituted by halogen, —NH 2 , —OH, C 1-3 alkyl or C 1-3 alkoxyl; or C 1-3 alkoxyl substituted by halogen, —NH 2 , —OH, C 1-3 alkyl or C 1-3 alkoxyl.

7. The compound of Formula I of claim 1 , wherein the substituent is selected from —F, —Cl, —Br, —OH, —NO 2 , —NH 2 , —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , —CN, C 1-6 alkyl, C 1-4 alkoxyl, C 1-4 alkoxyl-C 1-6 alkyl, C 3-8 cycloalkyl-C 1-8 alkyl, C 1-6 alkyl carbonyl, C 1-6 alkoxyl carbonyl, C 1-6 alkyl thiol, —S(O) 2 N(C 1-6 alkyl) 2 , —S(O) 2 C 1-6 alkyl, —N(C 1-6 alkyl)S(O) 2 N(C 1-6 alkyl) 2 , —S(O)N(C 1-6 alkyl) 2 , —S(O)(C 1-6 alkyl), —N(C 1-6 alkyl)S(O)N(C 1-6 alkyl) 2 , —N(C 1-6 alkyl)S(O)(C 1-6 alkyl), substituted or unsubstituted C 5-10 aryl, substituted or unsubstituted 5 to 10-membered heteroaryl, substituted or unsubstituted C 4-8 cyclic hydrocarbyl, or substituted or unsubstituted 4 to 8-membered heterocyclyl, wherein the heterocyclyl and heteroaryl comprise 1-4 heteroatoms selected from: N, O or S.

8. The compound of Formula I of claim 7 , wherein the substituent is selected from —F, —Cl, —Br, —OH, —NO 2 , —NH 2 , —NH(C 1-3 alkyl), —N(C 1-3 alkyl) 2 , —CN, C 1-3 alkyl, C 1-3 alkoxyl, C 1-3 alkyl carbonyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, phenyl, naphthyl, anthracyl, phenanthryl, fluorenyl, thiophenyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, benzopyrazolyl, indolyl, furanyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, indolizinyl, isoindolyl, indazolyl, isoindazolyl, purinyl, quinolinyl or isoquinolinyl.

9. The compound of Formula I of claim 8 , wherein the substituent is selected from —F, —Cl, —Br, —OH, —NO 2 , —NH 2 , —NH(C 1-3 alkyl), —N(C 1-3 alkyl) 2 , —CN, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, propoxy, isopropoxy or phenyl.

10. The compound of Formula I of claim 9 , wherein the ring C is selected from any of the following groups:

wherein:

X 5 , X 6 , X 7 , X 8 and X 9 are independently selected from N or CR d ; and at most 3 of X 5 , X 6 , X 7 , X 8 and X 9 are N simultaneously;

X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 and X 17 are independently selected from N or CR d ; and at most 5 of X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 and X 17 are N simultaneously;

X 18 , X 19 , X 20 and X 21 are independently selected from N or CR d , and at most 3 of X 18 , X 19 , X 20 and X 21 are N simultaneously;

R 6 and R 8 are independently selected from H, —NH 2 , —CN, —OH, —NO 2 , halogen, unsubstituted or halogenated C 1-6 alkyl, or unsubstituted or halogenated C 1-6 alkoxyl; and

R d is selected from H, halogen, unsubstituted or halogenated C 1-6 alkyl, or unsubstituted or halogenated C 1-6 alkoxyl.

11. The compound of Formula I of claim 10 , wherein the ring C is selected from any of the following groups:

wherein:

0, 1 or 2 of X 5 , X 6 , X 7 , X 8 and X 9 are N, and the others are CR d ;

0, 1 or 2 of X 18 , X 19 , X 20 and X 21 are N, and the others are CR d ;

R 6 is selected from H, —NH 2 , —CN, —OH, —NO 2 , —F, —Cl, —Br, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, fluorinated or brominated C 1-3 alkyl, fluorinated or brominated C 1-3 alkoxyl; and

R d is selected from H, —F, —Cl, —Br, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, fluorinated or brominated C 1-3 alkyl, or fluorinated or brominated C 1-3 alkoxyl.

12. The compound of Formula I of claim 11 , wherein the ring C is selected from any of the following groups:

13. The compound of Formula I of claim 1 , wherein the ring A is selected from substituted or unsubstituted C 4-6 cyclic hydrocarbyl, substituted or unsubstituted 4 to 6-membered heterocyclyl, substituted or unsubstituted C 5-6 aryl, or substituted or unsubstituted 5 to 6-membered heteroaryl, wherein the heterocyclyl or heteroaryl comprises 1-3 N atoms.

14. The compound of Formula I of claim 13 , wherein the ring A is selected from any of the following groups:

15. The compound of Formula I of claim 11 , wherein the ring A is selected from any of the following groups:

16. The compound of Formula I of claim 1 , wherein the compound has a structure selected from:

17. The compound of Formula I of claim 1 , wherein an atom of the isotope comprises but is not limited to hydrogen, carbon, nitrogen, oxygen, fluorine, phosphorus, chlorine or iodine; and preferably is 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 18 F, 31 P, 32 P, 35 S, 36 Cl or 125 I.

18. A pharmaceutical composition comprising:

(i) an effective amount of the compound of Formula I of claim 1 or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereoisomer, tautomer, solvate, isotope-substituted derivative, polymorph, prodrug or metabolite thereof; and

(ii) a pharmaceutically acceptable carrier.

Priority Claims (1)
CN 201811314910.1 · Nov 6, 2018 · national
Continuity (4)
Continuation 17014883 · Sep 8, 2020
Continuation 16908604 · Jun 22, 2020
Continuation PCTCN2019115754 · Nov 5, 2019
Related Publication 20240116949A1 · Apr 11, 2024
References Cited (3)
US 10844079B2 · Zheng · 2020 [cited by examiner]
US 11685748B2 · Zheng · 2023 [cited by examiner]
US 20230242551A1 · Zheng · 2023 [cited by examiner]